Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (589)	12/14/2006 6:09:19 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

That's why they wanted to keep the stock above $4.50 <g> In order to be able to sell 4.99M shares at $4.8096 <g> Introgen Therapeutics, Inc. Announces Financing Thursday December 14, 11:58 am ET AUSTIN, Texas, Dec. 14 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. (Nasdaq: INGN - News) today announced the sale of approximately 4.99 million shares of its common stock. Introgen will receive gross proceeds of approximately $24 million. Mulier Capital Limited acted as sole placement agent for the transaction, placing Introgen shares with institutional investors. The shares were offered on December 14, 2006 and were registered pursuant to the Company's existing shelf registration statement, which was declared effective by the U.S. Securities and Exchange Commission on August 25, 2003. Introgen anticipates using the net proceeds from the offering primarily for working capital and other general corporate purposes, including the development of its clinical programs which include ADVEXIN, INGN 241 and its other programs. Snip Bernard